ArticleFuture oncology (London, England)2024

Healthcare resource utilization and costs of chronic lymphocytic leukemia/small lymphocytic lymphoma patients who relapse or are refractory to ibrutinib.

Enrico De Nigris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.